Cargando…

In vitro and in vivo anti-tumor activity of alectinib in tumor cells with NCOA4-RET

Rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC) accounts for approximately 1–2% of all NSCLCs. To date, RET fusions that involve at least six fusion partners in NSCLC, such as KIF5B, CCDC6, NCOA4, TRIM33, CLIP1, and ERC1, have been identified. Recent clinical...

Descripción completa

Detalles Bibliográficos
Autores principales:	Arai, Sachiko, Kita, Kenji, Tanimoto, Azusa, Takeuchi, Shinji, Fukuda, Koji, Sato, Hiroshi, Yano, Seiji
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2017
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5650298/ https://www.ncbi.nlm.nih.gov/pubmed/29088743 http://dx.doi.org/10.18632/oncotarget.17900

Ejemplares similares

Glycogen synthase kinase‐3 inhibition overcomes epithelial‐mesenchymal transition‐associated resistance to osimertinib in EGFR‐mutant lung cancer
por: Fukuda, Koji, et al.
Publicado: (2020)

Receptor ligand-triggered resistance to alectinib and its circumvention by Hsp90 inhibition in EML4-ALK lung cancer cells
por: Tanimoto, Azusa, et al.
Publicado: (2014)

Phase 1/2 study of alectinib in RET-rearranged previously-treated non-small cell lung cancer (ALL-RET)
por: Takeuchi, Shinji, et al.
Publicado: (2021)

Severe Skin Toxicity Caused by Sequential Anti-PD-1 Antibody and Alectinib in Non-small-cell Lung Cancer: A Report of Two Cases and a Literature Review
por: Nishiyama, Akihiro, et al.
Publicado: (2021)

In vivo imaging xenograft models for the evaluation of anti‐brain tumor efficacy of targeted drugs
por: Kita, Kenji, et al.
Publicado: (2017)

Trametinib overcomes KRAS‐G12V–induced osimertinib resistance in a leptomeningeal carcinomatosis model of EGFR‐mutant lung cancer
por: Fukuda, Koji, et al.
Publicado: (2021)

Inhibition of EGFR and MEK surmounts entrectinib resistance in a brain metastasis model of NTRK1‐rearranged tumor cells
por: Suzuki, Chiaki, et al.
Publicado: (2022)

MET kinase inhibitor reverses resistance to entrectinib induced by hepatocyte growth factor in tumors with NTRK1 or ROS1 rearrangements
por: Takumi, Yohei, et al.
Publicado: (2022)

Patient‐derived xenograft models of non‐small cell lung cancer for evaluating targeted drug sensitivity and resistance
por: Kita, Kenji, et al.
Publicado: (2019)

NCOA4-RET fusion in colorectal cancer: Therapeutic challenge using patient-derived tumor cell lines
por: Kim, Sun Young, et al.
Publicado: (2018)

STAT3 inhibition suppresses adaptive survival of ALK-rearranged lung cancer cells through transcriptional modulation of apoptosis
por: Yanagimura, Naohiro, et al.
Publicado: (2022)

Amphiregulin triggered epidermal growth factor receptor activation confers in vivo crizotinib‐resistance of EML4‐ALK lung cancer and circumvention by epidermal growth factor receptor inhibitors
por: Taniguchi, Hirokazu, et al.
Publicado: (2016)

In vivo imaging models of bone and brain metastases and pleural carcinomatosis with a novel human EML4-ALK lung cancer cell line
por: Nanjo, Shigeki, et al.
Publicado: (2015)

Impact of MET inhibition on small‐cell lung cancer cells showing aberrant activation of the hepatocyte growth factor/MET pathway
por: Taniguchi, Hirokazu, et al.
Publicado: (2017)

Reduced doses of dabrafenib and trametinib combination therapy for BRAF V600E-mutant non-small cell lung cancer prevent rhabdomyolysis and maintain tumor shrinkage: a case report
por: Adachi, Yuta, et al.
Publicado: (2020)

Pulmonary carcinosarcoma showing an obvious response to pazopanib: a case report
por: Tanimoto, Azusa, et al.
Publicado: (2018)

Transient IGF-1R inhibition combined with osimertinib eradicates AXL-low expressing EGFR mutated lung cancer
por: Wang, Rong, et al.
Publicado: (2020)

Phase I study of vorinostat with gefitinib in BIM deletion polymorphism/epidermal growth factor receptor mutation double‐positive lung cancer
por: Takeuchi, Shinji, et al.
Publicado: (2020)

Podoplanin promotes progression of malignant pleural mesothelioma by regulating motility and focus formation
por: Takeuchi, Shinji, et al.
Publicado: (2017)

Precision oncology for RET-related tumors
por: Verrienti, Antonella, et al.
Publicado: (2022)

Mediastinal Malignant Melanoma Markedly Shrinking in Response to Nivolumab
por: Sakaguchi, Hiroyuki, et al.
Publicado: (2021)

Targeting the NCOA3-SP1-TERT axis for tumor growth in hepatocellular carcinoma
por: Li, Wenbin, et al.
Publicado: (2020)

MET amplification results in heterogeneous responses to osimertinib in EGFR‐mutant lung cancer treated with erlotinib
por: Nishiyama, Akihiro, et al.
Publicado: (2020)

Metabolites of alectinib in human: their identification and pharmacological activity
por: Sato-Nakai, Mika, et al.
Publicado: (2017)

Alterations of RET, Oncogene in Human Adrenal Tumors
por: Lin, Shiu‐Ru, et al.
Publicado: (1998)

A novel tumor suppressor gene NCOA5 is correlated with progression in papillary thyroid carcinoma
por: Zheng, Zhou-Ci, et al.
Publicado: (2018)

Inhibitory Effects of Esculetin on Liver Cancer Through Triggering NCOA4 Pathway-Mediation Ferritinophagy in vivo and in vitro
por: Xiu, Zhiru, et al.
Publicado: (2023)

Bronchoesophageal fistula formation after three courses of nivolumab for carcinoma of unknown primary with a subgroup of lung squamous cell carcinoma
por: Nishiyama, Akihiro, et al.
Publicado: (2020)

Inflammatory myofibroblastic tumor of the mesentery with a SQSTM1::ALK fusion responding to alectinib
por: Sunga, Cass G. G., et al.
Publicado: (2023)

Ependymoma‐like tumor with mesenchymal differentiation harboring C11orf95‐NCOA1/2 or ‐RELA fusion: A hitherto unclassified tumor related to ependymoma
por: Tomomasa, Ran, et al.
Publicado: (2021)

Detection of a somatic GREB1-NCOA1 gene fusion in a uterine tumor resembling ovarian sex cord tumor (UTROSCT)
por: Grither, Whitney R., et al.
Publicado: (2020)

RET is a potential tumor suppressor gene in colorectal cancer
por: Luo, Yanxin, et al.
Publicado: (2012)

Activity of the Highly Specific RET Inhibitor Selpercatinib (LOXO-292) in Pediatric Patients With Tumors Harboring RET Gene Alterations
por: Ortiz, Michael V., et al.
Publicado: (2020)

Small molecule inhibitor regorafenib inhibits RET signaling in neuroblastoma cells and effectively suppresses tumor growth in vivo
por: Chen, Zhenghu, et al.
Publicado: (2017)

Alectinib (CH5424802) antagonizes ABCB1- and ABCG2-mediated multidrug resistance in vitro, in vivo and ex vivo
por: Yang, Ke, et al.
Publicado: (2017)

Recurrent uterine inflammatory myofibroblastic tumor previously managed as leiomyosarcoma has sustained response to alectinib
por: Carballo, Erica V., et al.
Publicado: (2022)

The Role of NCOA4-Mediated Ferritinophagy in Health and Disease
por: Santana-Codina, Naiara, et al.
Publicado: (2018)

Nuclear Receptor Coactivators (NCOAs) and Corepressors (NCORs) in the Brain
por: Sun, Zheng, et al.
Publicado: (2020)

Crystal structure of the TLDc domain of human NCOA7-AS
por: Arnaud-Arnould, Mary, et al.
Publicado: (2021)

NCOA4: More than a receptor for ferritinophagy
por: Wang, Zheng, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_n6eiuv25ekfng7dpg3tcq3hcbp